Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t
Go back to Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 220.83 -3.68 (1.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $224.51 | 52 Week High | $333.65 | |||
| Open | $221.15 | 52 Week Low | $223.02 | |||
| Day High | $223.82 | P/E | 28.28 | |||
| Day Low | $219.82 | EPS | $7.81 | |||
| Volume | 465,108 | |||||
| (NASDAQ: STOK) | Delayed: 29.81 -0.18 (0.6%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $29.99 | 52 Week High | $ | |||
| Open | $29.41 | 52 Week Low | $ | |||
| Day High | $30.03 | P/E | N/A | |||
| Day Low | $29.15 | EPS | $ | |||
| Volume | 714,013 | |||||
